论文部分内容阅读
目的:检测黑色素瘤抗原基因MAGEA1和MAGEA3在喉鳞癌组织中的表达,探讨其作为喉癌免疫治疗靶标的可行性及其与喉癌生物学行为的关系。方法:采用免疫组化PV9000两步法检测69例喉鳞癌原发灶及其常规病理报告为阳性的121枚颈淋巴结中MAGEA1和MAGEA3的表达,同时采用蛋白质印迹法检测其在喉癌标本的癌中心区(TC),癌周0.5和1.0 cm及9例喉正常黏膜组织中的表达,并结合临床病理资料进行分析。结果:69例喉鳞癌组织中,MAGEA1蛋白的阳性表达率为58.0%(40/69),MAGEA3蛋白的阳性表达率为29.0%(20/69)。两种蛋白在癌中心区,癌周0.5和1.0 cm区中的表达逐渐下降(P<0.05),9例喉正常黏膜组织中无表达。MAGEA1和MAGEA3表达与肿瘤的T分期无关(P>0.05),MAGEA1蛋白的表达与病理分级相关(P<0.05),伴淋巴结转移的患者MAGEA3的表达率高于未转移者(P<0.05),颈转移淋巴结中两种蛋白的表达均下调。结论:MAGEA1和MAGEA3在喉鳞癌组织中特异高表达,可能以某种方式参与了喉癌的发生、发展,是进行喉癌免疫治疗的理想靶分子之一。
Objective: To detect the expression of melanoma antigen genes MAGEA1 and MAGEA3 in laryngeal squamous cell carcinoma (LSCC) and to explore their feasibility as target of laryngocarcinoma immunotherapy and its relationship with the biological behavior of laryngeal cancer. Methods: Immunohistochemistry PV9000 two-step method was used to detect the expression of MAGEA1 and MAGEA3 in 69 cases of primary laryngeal squamous cell carcinoma and 121 cases of normal cervical lymph nodes. Western blotting was used to detect the expression of MAGEA1 and MAGEA3 in laryngeal carcinoma specimens Cancer Center (TC), Pericancerous lesions at 0.5 and 1.0 cm and 9 cases of laryngeal normal mucosa, and analyzed with clinicopathological data. Results: The positive expression rate of MAGEA1 protein in 69 cases of laryngeal squamous cell carcinoma was 58.0% (40/69), and the positive expression rate of MAGEA3 protein was 29.0% (20/69). The expressions of both proteins in the central and periventricular cancerous areas decreased gradually (P <0.05), while in the normal laryngeal mucosa, no expression was found in the 9 normal tissues. The expression of MAGEA1 and MAGEA3 was not related to T stage (P> 0.05). The expression of MAGEA1 was correlated with pathological grade (P <0.05). The expression of MAGEA3 in patients with lymph node metastasis was higher than that without metastasis (P <0.05) The expression of both proteins in cervical lymph node was down-regulated. Conclusion: MAGEA1 and MAGEA3 are highly expressed in laryngeal squamous cell carcinoma and may be involved in the development of laryngeal carcinoma in some way. It is one of the ideal target molecules for laryngeal cancer immunotherapy.